CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 162 enrolled
Drug / intervention
Manifest refraction +2 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02842151
NCT02842151N/ACompleted
CompareCT.gov

Optimizing the Assessment of Refractive Outcomes After Cataract Surgery and Implantation of a Monofocal IOL

Alcon Research·interventional·Posted Jul 22, 2016·Updated Jan 8, 2019

In Brief

A clinical study evaluating Manifest refraction, ACRYSOF® IQ Monofocal IOL Model SN60WF, and 1 other intervention for Cataract. Completed, enrolled 162 participants.

Detailed Summary

The purpose of this study is to evaluate current available assessments (automated vs. manual) with which manifest refraction data and biometric variables are obtained to understand if data from an automated refractor can be utilized to optimize the A-constant as well as manual subjective refraction (ie, to a clinically insignificant difference). The A-constant is the calculated number that helps the surgeon determine which IOL should be implanted in the eye during cataract surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJul 22, 2016
Enrollment StartSep 21, 2016
Primary CompletionNov 16, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.9 years ago

Interventions

Manifest refractionprocedure

Manifest refraction performed by autorefraction (automated) and manual procedures (standard)

ACRYSOF® IQ Monofocal IOL Model SN60WFdevice

Monofocal IOL implanted for long-term use over the lifetime of the cataract patient

Topcon® KR-1W Wave-Front Analyzerdevice

Wavefront and topography system used to obtain autorefraction data